Volume 8, Number 7—July 2002
Research
Monitoring Antimicrobial Use and Resistance: Comparison with a National Benchmark on Reducing Vancomycin Use and Vancomycin-Resistant Enterococci
Table
Vancomycin use prescribing practice change | No. of ICUs (%) | Vancomycin use before and after practice change |
p valuec | |||
---|---|---|---|---|---|---|
(n=50) | Change absent |
Change present |
||||
Before | After | Before | After | |||
Hospitalwided | 22 (44%) | |||||
Drug use evaluation | 19 (38%) | 74.2 | 80.5 | 105.3 | 94.1 | 0.62 |
Redistributed HICPAC guidelines on VRE | 9 (18%) | 79.4 | 84.6 | 116.0 | 90.6 | 0.34 |
Prior approval of vancomycin required | 3 (6%) | 87.2 | 99.4 | 84.7 | 67.2 | 0.25 |
Unit-specificd | 11 (22%) | |||||
ICU-specific education on appropriate vancomycin use | 9 (18%) | 75.9 | 96.3 | 83.3 | 132.1 | 0.01 |
Removed vancomycin from surgical prophylaxis |
3 (6%) |
82.0 |
82.2 |
85.9 |
149.1 |
0.01 |
aDefined daily doses per 1,000 patient-days. bAbbreviations: ICARE, Intensive Care Antimicrobial Resistance Epidemiology; ICU, intensive-care units; HICPAC, Healthcare Infection control Practices Advisory Committee; VRE, vancomycin-resistant enterococci. cPaired t-test. dComponents of each major categories are not mutually exclusive, so one ICU may be represented in several components of each category. |
Page created: April 19, 2012
Page updated: April 19, 2012
Page reviewed: April 19, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.